• 1
    Miller PD, Chines AA, Christiansen C, Hoeck HC, Kendler DL, Lewiecki EM, Woodson G, Levine AB, Constantine G, Delmas PD. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res. 2008;23:52535.
  • 2
    Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ, Constantine GD, Chines AA. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res. 2008;23:192334.
  • 3
    European Medicines Agency. Evaluation of Medicines for Human Use. Assessment Report for Conbriza. Procedure No. EMEA/H/C/913 [Internet]. London: European Medicines Agency; 2009 Feb 19 [cited 2012 Nov 19]. Available from
  • 4
    Taylor RS, Drummond MF, Salkeld G, Sullivan SD. Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. BMJ. 2004;329:9725.
  • 5
    Borgstrom F, Strom O, Kleman M, McCloskey E, Johansson H, Odén A, Kanis JA. Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective. Osteoporos Int. 2011;22:95565.
  • 6
    Strom O, Borgstrom F, Kleman M, McCloskey E, Odén A, Johansson H, Kanis JA. FRAX and its applications in health economics—cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example. Bone. 2010;47:4307.
  • 7
    Hiligsmann M, Reginster JY. Health economics analyses in osteoporosis. In: SR, Arinoviche MM, Arriagada, editors. Temas de osteoporosis y otras enfermedades oseas. Santiago, Chile: Fundacion Chilena de osteoporosis p. 33758. 2012.
  • 8
    Kanis JA, Borgstrom F, Johnell O, Oden A, Sykes D, Jönsson B. Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporos Int. 2005;16:1525.
  • 9
    Borgstrom F, Johnell O, Kanis JA, Oden A, Sykes D, Jönsson B. Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics. 2004;22:115365.
  • 10
    Hiligsmann M, Ethgen O, Bruyère O, Richy F, Gathon HJ, Reginster JY. Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis. Value Health. 2009;12:68796.
  • 11
    Hiligsmann M, Bruyère O, Reginster JY. Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years. Bone. 2010;46:4406.
  • 12
    Hiligsmann M, Bruyère O, Reginster JY. Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women. Osteoporos Int. 2010;21:15765.
  • 13
    Hiligsmann M, Reginster JY. Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women. Bone. 2010;47:3440.
  • 14
    Hiligsmann M, Reginster JY. Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium. Pharmacoeconomics. 2011;29:89511.
  • 15
    Hiligsmann M, Gathon HJ, Bruyère O, Ethgen O, Rabenda V, Reginster JY. Cost-effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence. Value Health. 2010;13:394401.
  • 16
    Hiligsmann M, Rabenda V, Bruyère O, Reginster JY. The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy. 2010;96:1707.
  • 17
    Hiligsmann M, Rabenda V, Gathon HJ, Ethgen O, Reginster JY. Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int. 2010;86:20210.
  • 18
    Hiligsmann M, McGowan B, Bennett K, Barry M, Reginster JY. The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland. Value Health. 2012;15:60412.
  • 19
    Cleemput I, van Wilder P, Huybrechts M, Vrijens F. Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests. Value Health. 2009;12:4419.
  • 20
    Hiligsmann M, Bruyère O, Roberfroid D, Dubois C, Parmentier Y, Carton J, Detilleux J, Gillet P, Reginster JY. Trends in hip fracture incidence and in the prescription of antiosteoporosis medications during the same time period in Belgium (2000–2007). Arthritis Care Res (Hoboken). 2012;64:74450.
  • 21
    Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, De Laet C, Jonsson B. Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int. 2000;11:66974.
  • 22
    Johansson H, Kanis JA, McCloskey EV, Odén A, Devogelaer JP, Kaufman JM, Neuprez A, Hiligsmann M, Bruyere O, Reginster JY. A FRAX® model for the assessment of fracture probability in Belgium. Osteoporos Int. 2011;22:45361.
  • 23
    Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A. The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int. 2001;12:41727.
  • 24
    Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, Johnston CC Jr, Lindsay R. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int. 1998;8:46889.
  • 25
    Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312:12549.
  • 26
    Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, Eisman JA, Fujiwara S, Kroger H, Mellstrom D, Meunier PJ, Melton LJ 3rd, O'Neill T, Pols H, Reeve J, Silman A, Tenenhouse A. Predictive value of BMD for hip and other fractures. J Bone Miner Res. 2005;20:118594.
  • 27
    Haentjens P, Magaziner J, Colón-Emeric CS, Vanderschueren D, Milisen K, Velkeniers B, Boonen S. Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med. 2010;152:38090.
  • 28
    Johnell O, Kanis JA, Odén A, Sernbo I, Redlund-Johnell I, Petterson C, De Laet C, Jönsson B. Mortality after osteoporotic fractures. Osteoporos Int. 2004;15:3842.
  • 29
    Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B. Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int. 2004;15:10812.
  • 30
    Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK. The components of excess mortality after hip fracture. Bone. 2003;32:46873.
  • 31
    Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D. Risk of mortality following clinical fractures. Osteoporos Int. 2000;11:55661.
  • 32
    Hiligsmann M, Gathon HJ, Bruyère O, Daubie M, Parmentier Y, Dercq JP, Reginster JY. Hospitalisation costs of hip fractures in Belgium.. Osteoporos Int. 2011 Mar; 22 (Suppl 1):S332. [Abstracts of the 11th European Congress on Osteoporosis & Osteoarthritis (ECCEO11-IOF). Poster Presentation Abstracts. P531].
  • 33
    Autier P, Haentjens P, Bentin J, Baillon JM, Grivegnée AR, Closon MC, Boonen S. Costs induced by hip fractures: a prospective controlled study in Belgium. Belgian Hip Fracture Study Group. Osteoporos Int. 2000;11:37380.
  • 34
    Reginster JY, Gillet P, Ben Sedrine W, Brands G, Ethgen O, de Froidmont C, Gosset C. Direct costs of hip fractures in patients over 60 years of age in Belgium. Pharmacoeconomics. 1999;15:50714.
  • 35
    Melton LJ 3rd, Gabriel SE, Crowson CS, Tosteson AN, Johnell O, Kanis JA. Cost-equivalence of different osteoporotic fractures. Osteoporos Int. 2003;14:3838.
  • 36
    Hiligsmann M, Ethgen O, Richy F, Reginster JY. Utility values associated with osteoporotic fracture: a systematic review of the literature. Calcif Tissue Int. 2008;82:28892.
  • 37
    Silverman SL, Minshall ME, Shen W, Harper KD. Xie S; Health-Related Quality of Life Subgroup of the Multiple Outcomes of Raloxifene Evaluation Study. The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study. Arthritis Rheum. 2001;44:26119.
  • 38
    Salaffi F, Cimmino MA, Malavolta N, Carotti M, Di Matteo L, Scendoni P. Grassi W; Italian Multicentre Osteoporotic Fracture Study Group. The burden of prevalent fractures on health-related quality of life in postmenopausal women with osteoporosis: the IMOF study. J Rheumatol. 2007;34:155160.
  • 39
    Belgian Center for Pharmacotherapeutic Information. Répertoire Commenté des Médicaments [Internet]. Gent, Belgium: Centre Belge d'Information Pharmacothérapeutique (C.B.I.P. ASBL); 2012 [cited 2012 Nov 18]. Available from: French.
  • 40
    Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM. Melton LJ 3rd. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158:58593.
  • 41
    Verso M, Agnelli G, Ageno W, Imberti D, Moia M, Palareti G, Pistelli R, Cantone V. MASTER investigators. Long-term death and recurrence in patients with acute venous thromboembolism: The MASTER registry. Thromb Res. 2012;130:36973.
  • 42
    Haentjens P, De Groote K, Annemans L. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis. Arch Orthop Trauma Surg. 2004;124:50717.
  • 43
    Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, Stepan JJ, Powles TJ, Morrow M, Costa A, Silfen SL, Walls EL, Schmitt H, Muchmore DB, Jordan VC, Ste-Marie LG. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat. 2001;65:12534.
  • 44
    Belgian Cancer Registry. Belgium: Females, age-specific and age-standardised incidence rates of cancer, by primary site in 2009 (n/100,000 person years) [Internet]. Brussels, Belgium: Belgian Cancer Registry [cited 2012 Nov 19]. Available from:
  • 45
    Broekx S, Den Hond E, Torfs R, Remacle A, Mertens R, D'Hooghe T, Neven P, Christiaens MR, Simoens S. The costs of breast cancer prior to and following diagnosis. Eur J Health Econ. 2011;12:3117.
  • 46
    Ivergård M, Ström O, Borgström F, Burge RT, Tosteson AN, Kanis J. Identifying cost-effective treatment with raloxifene in postmenopausal women using risk algorithms for fractures and invasive breast cancer. Bone. 2010;47:96674.
  • 47
    Lidgren M, Wilking N, Jönsson B, Rehnberg C. Health related quality of life in different states of breast cancer. Qual Life Res. 2007;16:107381.
  • 48
    Fenwick E, Byford S. A guide to cost-effectiveness acceptability curves. Br J Psychiatry. 2005;187:1068.
  • 49
    Jönsson B, Ström O, Eisman JA, Papaioannou A, Siris ES, Tosteson A, Kanis JA. Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int. 2011;22:96782.
  • 50
    Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P. Rosen C; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev. 2002;23:5708.
  • 51
    Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F. Rizzoli R; European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2008;19:399428.
  • 52
    Hiligsmann M, Boonen A, Rabenda V, Reginster JY. The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis. Expert Rev Pharmacoecon Outcomes Res. 2012;12:15966.
  • 53
    Kanis JA, Cooper C, Hiligsmann M, Rabenda V, Reginster JY, Rizzoli R. Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporos Int. 2011;22:256573.
  • 54
    Kanis JA, Johansson H, Oden A, McCloskey EV. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone. 2009;44:104954.